Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. After confirmation of 6-months stability of tech-transfer batch, the work has been initiated, with preliminary data packages available by the second half of September, well within the proposed timelines. Pre-Close Trading Update; US OTC QB Market Application. &

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

The Cannigma

FEBRUARY 1, 2023

Even if a cannabinoid has shown promise on one cancer line, that doesn’t mean it will work for all cancers – even if it’s within the same organ system. Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. We were able to rapidly incorporate the FDA’s feedback into the design of the current Phase 2 trial to make the data generated in Europe as relevant as possible for a potential future NDA submission. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

NOVEMBER 12, 2021

THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP).

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

JULY 12, 2019

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

AUGUST 29, 2021

This export also validates the emergence of the global cannabinoid sector with reliance on quality, traceability and sustainability that Avicanna ’s Aureus products offer. To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

JULY 29, 2021

With Avicanna’s dedication to quality standards and pharmaceutical positioning we are poised to be a significant long-term player in the European medical market that is predominantly focused on medical utility of cannabinoids and where meeting EU pharmacopeia standards are essential.”.

Extraction 98

Extraction Supply Chain THC Research and Development 98

Canna Law Blog

JULY 15, 2019

Currently, seven of Canada’s top ten cannabis patent holders are major multi-national pharmaceutical companies, according to a joint research project by Washington D.C.-based based New Frontier Data and London-based cannabis bio-technology firm, Grow Biotech. As we’ve referenced before , data shows that the number of U.S.

Pharmaceutical 104

Pharmaceutical Research and Development Data Cannabinoids 104

Veriheal

OCTOBER 29, 2020

Is the focus on the negative impact due to the fact that role players want cannabis to remain illicit as to avoid its potential role in replacing pharmaceutical medication? The data for this graphic was provided by Jim Hudson at Hellth.com. . Scenario 2: Pharmaceuticals. However, the focus of funding remains on negative impacts.

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

The Cannigma

FEBRUARY 16, 2021

They require a process in which THC or other cannabinoid particles are reduced to nanoscopic size that allows them to then be mixed with water or other aqueous liquids. There is not extensive safety data available, however. The nanoemulsion method ALT uses is effective for all cannabinoids, not only THC, he said. Shutterstock).

Edibles 137

Edibles Digestion Tincture Cannabinoids 137

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? There are many different medical cannabis products. .

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. 11,141,404, titled “Formulations And Methods For Treating Acute Cannabinoid Overdose.” ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Project CBD

JANUARY 25, 2023

Statin medications deplete cannabinoid receptor function, according to a recent study by a team of distinguished Italian scientists. More troublesome, though, is that simvastatin alters genes involved in regulating cannabinoid receptors. Simvastatin also reduces cannabinoid receptor expression.

Cannabinoids 130

Cannabinoids Patients Data Extraction 130

Cannabis Law Report

JULY 27, 2021

NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S.,

Pharmaceutical 76

Pharmaceutical Research and Development Sativa Extraction 76

The Cannigma

JUNE 14, 2021

We are allowed to cultivate, manufacture, research, analyze and distribute cannabis for scientifical, medical and pharmaceutical research. Second, it can change the content of both THC and potentially other cannabinoids and third, hopefully it will allow for testing different delivery methods.”. Shutterstock). A promise made years ago.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

CannaMD

NOVEMBER 22, 2020

Unfortunately, most traditional pharmaceutical options are distinctly lacking due to side effects, as well as a bit of trepidation (although Botox, one current treatment option for migraines, has gained popularity). Patients used the app, Strainprint, which allowed data to be archived and studied.

Marijuana 116

Marijuana Treatment Patients Cannabinoids 116

Canna Law Blog

FEBRUARY 21, 2020

The EFSA guidance on cannabinoids strongly echoes the U.S. Although the UK recently severed its ties with the European Union, the FSA has opted to align its policy with that of the European Food Safety Authority (“ EFSA ”).

Food 114

Food CBD Legalization Hemp 114

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Pharmaceutical 98

Pharmaceutical Research and Development Epilepsy Medicine 98

Veriheal

JANUARY 26, 2023

Most commonly, pharmaceutical medication is prescribed to regulate moods. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients. Thus, this groundbreaking study laid the foundation for understanding how cannabinoids can support mental health.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Greencamp

FEBRUARY 2, 2019

Even though cannabis and cannabinoid-derived pharmaceuticals are both frequently used by HIV/AIDS patients, several studies show that something interesting happens when cannabis is consumed. How classical pharmaceuticals fight HIV. What is HIV and how is it manifested? There are many different cell types in the human body.

Marijuana 110

Marijuana Therapy Cannabinoids Patients 110

United Patients Group

MAY 17, 2023

Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention. Cannabinoids have been shown to help people with autism manage anxiety and stress.

Sleep 105

Sleep Cannabinoids Patients CBD 105

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Forward-looking statements.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

CannaMD

JULY 23, 2020

In the novel study conducted by researchers at the University of New Mexico, nearly 2,000 people self-administered cannabis over a three-year period and reported their marijuana use via the Releaf App that was specifically designed for the study’s data collection needs. Furthermore, THC and CBD may have a synergistic effect.

Data 114

Data Chronic Pain Sleep Patients 114

Veriheal

JANUARY 4, 2021

In adults with chronic pain, what are the harms of cannabinoids? In adults with chronic pain, what are the benefits of cannabinoids? Cannabis is a plant loaded with cannabinoids like THC , CBN , CBG , CBD , and others. Medicinal cannabinoid therapies are saving and changing lives for people across America and around the world.

Chronic Pain 105

Chronic Pain Therapy Cannabinoids Treatment 105

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

The two active cannabinoids in marijuana are cannabidiol (CBD) and tetrahydrocannabinol (THC), the latter of which causes psychoactive effects while the former does not. This system naturally produces cannabinoids in the bloodstream, but chronic stress, anxiety, and other stimuli can stifle the production of natural endocannabinoids.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

AUGUST 11, 2021

(“Avicanna”), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products. The Branded Products include Avicanna’s proprietary cannabinoid topical formulations developed through years of extensive research by Avicanna’s team of scientists.

Topical 75

Topical Research and Development Seed-To-Sale Pharmaceutical 75

The Cannigma

FEBRUARY 11, 2021

Listen & Subscribe: When Mara Gordon started using medical cannabis there wasn’t any lab testing — or any way to know how much of each cannabinoid or terpene was in a given strain. One of the things she does is collect and analyze data about cannabis products and how patients with different medical conditions respond to them.

Wellness and Beauty 125

Wellness and Beauty Data Patients Medicine 125

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 108

Research and Development Data THC Clinical Trials 108

CannaMD

NOVEMBER 6, 2019

And so, in light of America’s ongoing struggle with a sweeping opioid crisis of addiction and overdose deaths, it makes sense that there is a growing interest both among the public and the medical community in the possibilities of medical marijuana as an alternative to pharmaceuticals for pain management. million to 11.4 million to 11.4

Marijuana 107

Marijuana Patients Clinical Trials Data 107

Cannabis Law Report

NOVEMBER 24, 2019

Building the bridge between brands and the marketplace through testing and the importance of good data. A need for data at all of these levels and data specific to product type drives more advanced methodology in the laboratories, often resulting in a better understanding of the matrix and more accurate data.

Business 95

Business Data Wellness and Beauty Safety 95

Cannabis Law Report

AUGUST 14, 2021

Mary AG’s joint venture Yunnan Moquan and CBDer are currently the only companies licensed for indoor industrial hemp cultivation in China’s only legalized province for cannabinoid extraction. The MOU mainly encompasses: Working with CBDer to further develop China’s industrial hemp market. About Mary Agrotechnologies Inc.

Hemp 105

Hemp Supply Chain Cannabinoids Extraction 105